Does CANAKINUMAB Cause Injection site extravasation? 24 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Injection site extravasation have been filed in association with CANAKINUMAB (Ilaris). This represents 0.2% of all adverse event reports for CANAKINUMAB.
24
Reports of Injection site extravasation with CANAKINUMAB
0.2%
of all CANAKINUMAB reports
0
Deaths
16
Hospitalizations
How Dangerous Is Injection site extravasation From CANAKINUMAB?
Of the 24 reports, 16 (66.7%) required hospitalization.
Is Injection site extravasation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAKINUMAB. However, 24 reports have been filed with the FAERS database.
What Other Side Effects Does CANAKINUMAB Cause?
Pyrexia (1,327)
Inappropriate schedule of drug administration (1,238)
Drug ineffective (1,078)
Inappropriate schedule of product administration (944)
Pain (858)
Condition aggravated (771)
Malaise (684)
Off label use (557)
Arthralgia (555)
Rash (505)
What Other Drugs Cause Injection site extravasation?
EXENATIDE (2,320)
ETANERCEPT (1,139)
ADALIMUMAB (381)
SEMAGLUTIDE (342)
VEDOLIZUMAB (237)
SOMATROPIN (230)
REGADENOSON (226)
RITUXIMAB (215)
EVOLOCUMAB (188)
DUPILUMAB (170)
Which CANAKINUMAB Alternatives Have Lower Injection site extravasation Risk?
CANAKINUMAB vs CANDESARTAN
CANAKINUMAB vs CANDESARTAN CILEXETIL
CANAKINUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE
CANAKINUMAB vs CANGRELOR
CANAKINUMAB vs CANIS LUPUS FAMILIARIS SKIN